For twenty-five years, Sampaio worked within the Federal University of Rio de Janeiro, focusing on a single, cross-shaped protein called laminin. Under the electron microscope, the molecule reveals itself as a delicate, asymmetrical crucifix. In the womb, it acts as a guide, forming the structural networks that allow a fetus to grow its complex web of nerves. In the adult body, however, a traumatic spinal injury creates a different landscape: a dense, scarred barrier that prevents severed nerves from ever finding their way back to one another.
Sampaio’s discovery, which she named polylaminin, uses a purified version of this protein harvested from donated placentas. By processing the tissue in a mildly acidic solution, she found she could mimic the natural pH of an injured spine, causing the protein to assemble into a biological scaffold. This matrix provides the missing bridge, inviting the body’s own cells to traverse the gap left by trauma.
The transition from the laboratory to the bedside required more than scientific rigor; it required the patience of a builder. Sampaio secured R$3 million in funding and collaborated with the pharmaceutical company Cristália to produce the polymer. When the trials finally moved to humans, the protocol was strict. Patients with complete acute injuries received the treatment within seventy-two hours of their accident, the window of time before the internal scarring becomes permanent.
The results forced the independent monitoring committee to alter the study’s design. In a preliminary group of eight patients, six began to regain motor function. Most striking was the case of one individual who, after receiving the placental protein, returned to walking. This unexpected progress led the committee to recommend an open-label trial, allowing more patients to access the treatment while researchers continue to gather data on its efficacy.
Despite the sudden attention and dozens of requests for compassionate use, Sampaio remains anchored in the discipline of the clinic. She knows that the path from a lab bench in Rio to a global standard of care is long, yet the sight of a once-paralyzed limb moving of its own volition suggests that the bridge she built out of laminin is holding.